Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Abiomed Inc., EBITDA calculation
US$ in thousands
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Abiomed Inc. EBITDA increased from 2020 to 2021 but then decreased significantly from 2021 to 2022. |
Enterprise Value to EBITDA Ratio, Current
Abiomed Inc., current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (US$ in thousands) | |
| Enterprise value (EV) | 16,088,812) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 218,649) |
| Valuation Ratio | |
| EV/EBITDA | 73.58 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| Abbott Laboratories | 19.39 |
| Cigna Group | 10.17 |
| CVS Health Corp. | 6.40 |
| Elevance Health Inc. | 7.46 |
| Intuitive Surgical Inc. | 86.51 |
| Medtronic PLC | 15.87 |
| UnitedHealth Group Inc. | 13.87 |
| EV/EBITDA, Sector | |
| Health Care Equipment & Services | 14.72 |
| EV/EBITDA, Industry | |
| Health Care | 14.77 |
Based on: 10-K (reporting date: 2022-03-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Abiomed Inc., historical EV/EBITDA calculation, comparison to benchmarks
| Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Enterprise value (EV)1 | 9,983,091) | 12,099,179) | 8,382,834) | 11,359,861) | 17,182,479) | 5,740,561) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 218,649) | 312,317) | 277,255) | 277,481) | 171,744) | 97,899) | |
| Valuation Ratio | |||||||
| EV/EBITDA3 | 45.66 | 38.74 | 30.24 | 40.94 | 100.05 | 58.64 | |
| Benchmarks | |||||||
| EV/EBITDA, Competitors4 | |||||||
| Abbott Laboratories | 15.85 | 17.42 | 25.99 | 21.70 | — | — | |
| Cigna Group | 8.88 | 9.06 | 6.31 | 8.42 | — | — | |
| CVS Health Corp. | 12.42 | 10.41 | 8.56 | 9.43 | — | — | |
| Elevance Health Inc. | 10.26 | 10.05 | 7.57 | 9.05 | — | — | |
| Intuitive Surgical Inc. | 41.52 | 44.54 | 59.12 | 37.53 | — | — | |
| Medtronic PLC | 14.99 | 24.41 | 17.92 | 16.01 | — | — | |
| UnitedHealth Group Inc. | 15.11 | 17.39 | 13.39 | 13.82 | — | — | |
| EV/EBITDA, Sector | |||||||
| Health Care Equipment & Services | 13.98 | 15.40 | 13.12 | 13.15 | — | — | |
| EV/EBITDA, Industry | |||||||
| Health Care | 13.71 | 13.87 | 16.50 | 14.37 | — | — | |
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).
3 2022 Calculation
EV/EBITDA = EV ÷ EBITDA
= 9,983,091 ÷ 218,649 = 45.66
4 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Abiomed Inc. EV/EBITDA ratio increased from 2020 to 2021 and from 2021 to 2022. |